United-Guardian Reports Second Quarter Financial Results

Rhea-AI Summary

United-Guardian, Inc. (NASDAQ:UG) reported a 24% increase in Q2 sales, reaching $3,657,978 compared to $2,954,644 in 2020. Net income rose from $1,186,611 ($0.26/share) to $1,344,524 ($0.29/share). For the first half of 2021, sales increased by 13% to $7,088,846, with net income rising from $1,976,918 ($0.43/share) to $2,525,726 ($0.55/share). A significant 68% growth in cosmetic ingredient sales was noted, although future projections remain uncertain due to the pandemic.

Positive

• 24% increase in Q2 sales year-over-year.
• 68% growth in cosmetic ingredient sales.
• Net income up to $1,344,524 in Q2 2021.

Negative

• Uncertainty about future sales impact due to the Delta variant.

HAUPPAUGE, N.Y., Aug. 11, 2021 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported today that sales in the second quarter of 2021 grew by 24% over the same quarter last year, increasing from $2,954,644 in 2020 to $3,657,978 this year, resulting in net income increasing from $1,186,611 ($0.26 per share) in the second quarter of 2020 to $1,344,524 ($0.29 per share) this year. For the first six months of the year sales increased by 13% from $6,277,558 in 2020 to $7,088,846 this year, with net income increasing from $1,976,918 ($0.43 per share) in 2020 to $2,525,726 ($0.55 per share) in the first six months of this year.

Ken Globus, President of United-Guardian, stated, “With the global economies starting to recover from the coronavirus pandemic in the second quarter of this year, sales of our cosmetic ingredients increased by 68% compared with the same period last year. This increase in sales of our cosmetic ingredients was the primary reason for the substantial increase in sales in the second quarter. In addition, we had strong sales of our pharmaceutical products, despite having discontinued our participation in state Medicaid programs due to the excessive fees involved. With the Delta variant of the coronavirus expected to impact global economies more significantly in the third quarter than it did in the second, it is difficult to project what the impact will be on sales of our cosmetic ingredients for the rest of the year. Regardless of the impact of the pandemic on our other sales, we expect our pharmaceutical sales to remain strong. We are very pleased with our year-to-date financial results, and are hopeful that despite the continuing impact of the pandemic, sales will continue to be resilient for the remainder of the year.”

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

Contact:	Ken Globus
	(631) 273-0900

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

Financial Results for the
Three and Six Months Ended
June 30, 2021 and 2020*

STATEMENTS OF INCOME
(unaudited)

		THREE MONTHS ENDED JUNE 30,								SIX MONTHS ENDED JUNE 30,
		2021				2020				2021				2020
Net sales		$	3,657,978			$	2,954,644			$	7,088,846			$	6,277,558
Costs and expenses:
Cost of sales			1,499,390				1,270,434				2,860,403				2,659,765
Operating expenses			513,012				511,635				970,139				1,026,910
Research and development expense			130,025				108,566				218,311				216,298
Total costs and expenses			2,142,427				1,890,635				4,048,853				3,902,973
Income from operations			1,515,551				1,064,009				3.039,993				2,374,585
Other income:
Investment income			45,640				48,319				85,400				92,386
Net gain on marketable securities			137,574				387,179				65,527				30,584
Total other income			183,214				435,498				150,927				122,970
Income before provision for income taxes			1,698,765				1,499,507				3,190,920				2,497,555
Provision for income taxes			354,241				312,896				665,194				520,637
NET INCOME		$	1,344,524			$	1,186,611			$	2,525,726			$	1,976,918
Earnings per common share (basic and diluted)		$	0.29			$	0.26			$	0.55			$	0.43
Weighted average shares (basic and diluted)			4,594,319				4,594,319				4,594,319				4,594,319

* Additional financial information can be found on the company’s web site at www.u-g.com.

FAQ

What were United-Guardian's Q2 2021 sales figures?

United-Guardian reported Q2 2021 sales of $3,657,978, a 24% increase from $2,954,644 in Q2 2020.

How did the net income change for United-Guardian in Q2 2021?

Net income rose to $1,344,524 in Q2 2021, up from $1,186,611 in Q2 2020.

What was the growth rate of cosmetic ingredient sales for United-Guardian?

Cosmetic ingredient sales grew by 68% compared to the same period last year.

What is United-Guardian's outlook regarding the pandemic's impact on sales?

The company anticipates uncertainty in sales due to the Delta variant's impact but expects strong pharmaceutical sales to continue.